|
Clinical characteristics and outcomes of CML in adolescents and young adults (Al Rabi K et al. Clin Lymphoma Myeloma Leuk, Oct 2024)
|
14 November 2024 |
|
A high proportion of germline variants in pediatric chronic myeloid leukemia in pediatric chronic myeloid leukemia (Krumbold M et al. Mol Cancer, Sept 2024)
|
30 October 2024 |
|
CAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast crisis (Kramp LJ et al. Ann Hematol, Sept 2024)
|
30 October 2024 |
|
Low-level BCR::ABL1 transcript at diagnosis in childhood leukemia: A 10-year single institution study (Cain LE et al. Genes Chromosomes Cancer, Sept 2024)
|
30 October 2024 |
|
Chronic myeloid leukemia in adolescents and young adults Clinicopathological variables and outcomes (Abdulla MA et al. Oncology, July 2024)
|
30 July 2024 |
|
Impact of tyrosine kinase inhibitors (TKIs) on growth in children and adolescents with CML: A systematic review (Katsarou D et al., Curr Pharm Des, July 2024)
|
30 July 2024 |
|
Childhood chronic myeloid leukemia treatment (PDQ) (PDQ Pediatric Treatment Editorial Board June, 2024)
|
04 July 2024 |
|
Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with CML: A prospective multicentre trial of the I-BFM Study Group (Pichler H et al. Br J Haematol, May 2024)
|
05 June 2024 |
|
Priapism and chronic myeloid leukemia in an adolescent. Rare debut presentation. A case report (Romero-Guerra AL et al. Arch Argent Pediatr, April 2024)
|
02 May 2024 |
|
Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia (Behrens YL et al. Haematologica, March 2024)
|
12 April 2024 |
|
Imatinib treatment and longitudinal growth in pediatric patients with CML: Influence of demographic, pharmacological, and genetic factors in the German CML-PAED Cohort (Stiehler S et al. Haematologica, March 2024)
|
12 April 2024 |
|
Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patient with chronic myeloid leukemia
|
12 April 2024 |
|
Chronic spontaneous urticarial as the presenting factor in a paediatric case of chronic myeloid leukemia (Sutton KM et al. Pediatr Blood Cancer, March 2024)
|
12 April 2024 |
|
Bosutinib in resistant and intolerant pediatric patients with chronic phase CML: Results from the Phase I part study ITCC054/COG AMML1921 (Brivio E et al. J Clin Oncol, March 2024)
|
12 April 2024 |
|
A 3-year old with chronic myeloid leukemia (Coty-Fatall Z & Richardson A. Blood, February 2024)
|
04 March 2024 |
|
Challenges in management of pediatric chronic myleloid leukemia (pCML) in the low- and middle income countries (LMICs): Insights from an Interntional CML Foundation (iCMLf) Multi National Study (Roy Moulik N et al. Pediatr Hematol Oncol, Jan 2024)
|
06 February 2024 |
|
Pediatric chronic myeloid leukemia P190 variant with IgA vasculitis: Rare association - case report (Shah K et al. Pediatr Blood Cancer, Jan 2024)
|
06 February 2024 |
|
Bosutinib: Pediatric first approval (Hoy SM et al. Paediatr Drugs, Dec 2023)
|
16 January 2024 |
|
Skin reactions to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia (Toker M et al. Pediatr Dermatol, Dec 2023)
|
16 January 2024 |
|
Treatment and follow-up of children with CML-CP in the TKI era - Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort (Roy Moulik N et al. Br J Haematol, Dec 2023)
|
16 January 2024 |
|
Chronic myeloid leukemia (CML) in children and adolescents - Clinicopathological findings (Nevejan L et al. Eur J Haematol, Nov 2023)
|
05 December 2023 |
|
Physiologically based pharmacokinetics modelling of nilotinib for drug-drug interactions, pediatric patients, and pregnancy and lactation (Liu XI et al. J Clin Pharmacol, Nov 2023)
|
05 December 2023 |
|
Continuous therapy response references for BCR::ABL1 in pediatric chronic myeloid leukemia (Volz C et al. Sci Rep, Oct 2023)
|
05 December 2023 |
|
Somatic variant profiling in chronic phase pediatric CML (Behrens YL et al. Haematologica, Sept 2023)
|
11 October 2023 |
|
The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study (Hijiya N et al. Blood Adv, Sept 2023)
|
11 October 2023 |
|
Priapism at diagnosis of pediatric chronic myeloid leukemia: Data derived from a large cohort of children and teenagers and a narrative review on priapism management (Suttorp M et al. J Clin Med
|
04 September 2023 |
|
Chronic myeloid leukemia in children and adolescents (Gotesman M et al. Adv Pediatr, Aug 2023)
|
30 August 2023 |
|
Effect of imatinib mesylate and growth in pediatric CML: A systematic review and meta-analysis (J Pediatr Hematol Oncol, July 2023)
|
31 July 2023 |
|
Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults (Mersin S et al. Expert Opin Pharmacother, July 2023)
|
31 July 2023 |
|
Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase CML in the tyrosine kinase inhibitor era (Ishida H et al. Am J Hematol, May 2023)
|
02 June 2023 |
|
Pediatric chronic myeloid leukemia in myeloid blast crisis (Dey B and Dutta A. Autpos Case Rep, April 2023)
|
02 June 2023 |
|
Recent progress in the management of pediatric chronic myeloid leukemia - Review (Shima H. and Shimada H. Int J Hematol, February 2023)
|
02 March 2023 |
|
Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations - Review (Sembill S et al. Leukemia, January 2023)
|
06 February 2023 |
|
Impact of tyrosine kinase inhibitors applied for first-line chronic myeloid leukemia treatment on platelet function in whole blood of healthy volunteers in vitro (Eckart F et al. Hamostaseologie, January 2023)
|
06 February 2023 |
|
Children with chronic myeloid leukemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicentre experience in Taiwan (Liu HC et al. Br J Cancer, January 2023)
|
06 February 2023 |
|
Relative bioavailability and food effect of asciminib pediatric mini-tablet formulation compared to the reference tablet formulation in healthy adult participants (Hoch M et al. Clin Pharmacol Drug Dev, January 2023)
|
06 February 2023 |
|
Patient-reported long-term outcome following allogeneic hematopoietic stem cell transplantation in pediatric chronic myeloid leukemia (Schleicher O et al. Front Oncol, September 2022)
|
03 January 2023 |
|
Recent progress in the management of pediatric chronic myeloid leukemia - Review (Shima H. and Shimada H. Int J Hematol, December 2022)
|
03 January 2023 |
|
Alterations in cellular metabolism after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review (Li C et al. Front Oncol, December 2022)
|
03 January 2023 |
|
Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors (Nishiyam-Fujita Y et al. Ann Med, December 2022)
|
03 January 2023 |
|
Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course (Delehaye F et al. Ann Hematol, Nov 2022)
|
07 December 2022 |
|
Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment (Karadas N et al. Int J Hematol, Nov 2022)
|
07 December 2022 |
|
Outcome of pediatric chronic myeloid leukemia with management focusing on gene transcript levels (Al-Ghamblas I et al. Int J Pediatr Adolesc Med, September 2022)
|
04 October 2022 |
|
Dasatinib-related pleural effusion and lymphocytosis rates are different between adult and pediatrc pts with Philadelphia chromosome-positive leukemias: are age and comorbidities only to blame? (Kiliçasian NA et al. Expert Rev Respir Med, September 2022)
|
04 October 2022 |
|
Secondary pseudotumor cerebri syndrome in a child with chronic myeloid leukemia: Report of a case and review of previous cases (Rasmussen AH et al. Pediatr Blood Cancer, September 2022)
|
04 October 2022 |
|
Management of CML in children and young adults (Ford M et al. Curr Hematol Malig Res, Aug 2022)
|
30 August 2022 |
|
Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia (Kim Y et al. Front Pediatr, Jul 2022)
|
30 August 2022 |
|
Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children's Cancer Group (Kodama Y et al. Int J Hematol, July 2022)
|
15 August 2022 |
|
Sensoineural hearing loss in juvenile CML: A Rare Case Report in Surabaya, Indonesia (Syamsuddin IK and Notopuro PB, Int Med Case Rep J, July 2022)
|
15 August 2022 |
|
Successful eradication of chronic myeloid leukemia in a child despite allogeneic graft rejection (Vuorenoja S et al. Cancer Rep (Hoboken), July 2022)
|
15 August 2022 |
|
Outcome prediction of chronic myeloid leukemia (CML) in children (Leung WY et al. Ann Hematol, June 2022)
|
30 June 2022 |
|
Pediatric chronic myelogenous leukemia in T-lineage blast crisis: A reminder in relevance
|
07 June 2022 |
|
Distribution and frequency of tyrosine kinase inhibitor-associated long-term complications in children with chronic myeloid leukemia
|
07 June 2022 |
|
Discontinuation of tyrosine kinase inhibitors in pediatrc chronic myeloid leukemia (Shima H et al. Pediatr Blood Cancer, April 2022)
|
02 May 2022 |
|
Prognostic factors for outcomes of allogeneic HSCT for children and adolescents/young adults with CML in the TKI era (Shimada H et al. Transplant Cell Ther, April 2022)
|
02 May 2022 |
|
Skin and soft tissue infections in adolescent chronic myeloid leukemia under dasatanib treatment (Uchida E et al. Pediatr Blood Cancer, April 2022)
|
02 May 2022 |
|
Therapeutic leukapharesis in pediatric leukemia: Utilization trend and early outcomes in a US Nationwide Cohort (Takahashi T et cl. J Pediatr Hematol Oncol, March 2022)
|
04 April 2022 |
|
Design and stability of pediatric oral formulation of imatinib (Hinterlang M et al. J Oncol Pharm Pract, March 2022)
|
04 April 2022 |
|
Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML (Smith SM et al. Pediatr Hematol Oncol, December 2021)
|
14 January 2022 |
|
Comparison of the transcriptomic signature in pediatric and adult CML (Youn M et al. Cancers(Basel), December 2021)
|
14 January 2022 |
|
Efficacy of ponatinib prior to and after allogeneic hematopoietic stem cell transplantation in an adolescent with chronic myeloid leukemia in blast phase (Lee JW et al. Blood Res, November 2021)
|
02 December 2021 |
|
Seven year long follow-up of patient with childhood chronic myeloid leukemia postsecond haploidentical stem cell transplant (Sachdev M et al. J Pediatr Hematol Oncol, November 2021)
|
02 December 2021 |
|
Pediatric chronic myeloid leukemia presenting with extreme thrombocytosis and acute upper gastrointestinal haemorrhage: A case report (Zhang Y et al. J Pediatr Hematol Oncol, Oct 2021)
|
29 October 2021 |
|
Chronic myeloid leukemia in children: immune function and vaccinations (Suttorp M et al. J Clin Med, September 2021)
|
30 September 2021 |
|
Discontinuation of imatinib in children with chronic myeloid leukemia: A study from the International Registry of Childhood CML (Millot F et al. Cancers(Basel), August 2021
|
01 September 2021 |
|
A phase 2 study of nilotinib in pediatric patients with CML: Long-term update on growth retardation and safety
|
29 July 2021 |
|
Adolescents experienced more treatment failure than children with CML receiving imatinib as frontline therapy: a retrospective multicentre study (Dou X et al. Ann Hematol, June 2021)
|
30 June 2021 |
|
Sudden blast phase in paediatric chronic myeloid leukemia-chronic phase with abnormal blasts detected by flow cytometry at diagnosis. Can it be considered a warning sign? (Vijayasekharan K et al. Cytometry B Clin Cymtom, May 2021)
|
31 May 2021 |
|
Tyrosine kinase inhibitors and beyond for chronic myeloid leukemia in children (Phillips LN and Hijiya N. Paediatr Drug, April 2021)
|
29 April 2021 |
|
Paediatric chronic myeloid leukemia presenting in de novo or secondary blast phase – a comparison of clinical and genetic characteristics (Sembill S et al. Br J Haematol, March 2021)
|
29 March 2021 |
|
Chronic myelogenous leukemia in childhood (Smith SM et al. Curr Oncol Rep, March 2021)
|
29 March 2021 |
|
Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: Single-Center experience from China (Cai Y et al. Int J Hematol, January 2021)
|
29 March 2021 |
|
Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia (Suttorp M et al. Cancers(Basel), February 2021)
|
02 February 2021 |
|
Successful haploidentical stem cell transplant with posttransplant cyclophosphamide for isolated central nervous system blast crisis in a child with CML (Chatterjee G et al. J Pediatr Hematol Oncol, January 2021)
|
02 February 2021 |
|
Factors and outcomes of chronic myeloid leukemia at very young age: Data from the International Pediatric Chronic Myeloid Leukemia Registry (Meral Günes A et al. Pediatr Blood Cancer, October 2020)
|
02 October 2020 |
|
Lymphoblastic predominance of blastic phase in children with chronic myeloid leukemia treated with imatinib: A report from the I-CML-Ped Study (Meyran D et al. Eur J Cancer, August 2020)
|
31 August 2020 |
|
A case of childhood blastic phase chronic myeloid leukemia with minor BCR-ABL (Yamanaka J et al. J Pediatr Hematol Oncol, August 2020)
|
31 August 2020 |
|
Pediatric chronic myeloid leukemia with myeloid blast crisis and complex karyotype at presentation (Sazawal S et al. Indian J Cancer, July - Sept 2020)
|
31 August 2020 |
|
Outcomes of children with chronic myeloid leukemia: A population-based cohort study (Egan G et al. Pediatr Blood Cancer, July 2020)
|
31 August 2020 |
|
BCR-ABL tyrosine kinase inhibitors in the treatment of pediatric CML (Carafiglio F et al. Int J Mol Sci, June 2020)
|
11 August 2020 |
|
Sustained molecular response following a failed attempt of tyrosine kinase inhibitor discontinuation and the effects on growth in a child with CML: not always a short story (Triche L et al. Pediatr Hematol, Oncol, August 2020)
|
11 August 2020 |
|
Ponatinib in childhood Philadelphia chromosome-positive leukemias: an International registry of childhood chronic myeloid leukemia study (Millot F et al. Eur J Cancer, July 2020)
|
01 July 2020 |
|
Imatinib-induced hypogammaglobulinemia in children and adolescents with chronic myeloid leukemia
|
02 June 2020 |
|
Vaccination with live attenuated vaccines in four children with chronic myeloid leukemia while on imatinib treatment
|
02 June 2020 |
|
Experience with ponatinib in paediatric patients with leukaemia
|
28 February 2020 |
|
Implementation of a physiologically based pharmacokinetic modeling approach to guide optimal dosing regimes for imatinib and potential drug interactions in paediatrics
|
28 February 2020 |
|
Pharmacokinetics of nilotinib in pediatric patients with Philadelphia Chromosome-positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia
|
28 February 2020 |
|
Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukemia
|
28 February 2020 |
|
Outcomes of allogeneic hematopoietic cell transplantion for childhood chronic myeloid leukemia: Single-center experience
|
28 February 2020 |
|
Discontinuation of tyrosine kinase inhibitor in a child with chronic myeloid leukemia
|
03 February 2020 |
|
Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukemia in children
|
03 December 2019 |
|
Acquired neuro-secretory defect in growth hormone secretion due to imatinib mesylate and the efficacy of growth hormone therapy in children with chronic myeloid leukemia
|
03 December 2019 |
|
Discontinuation of tyrosine kinase inhibitor in children with chronic myeloid leukemia (JPLSG STKI-14 study)
|
03 December 2019 |
|
Successful haploidentical stem cell transplant with post-transplant cyclophosphamide for isolated central nervous system blast crisis in a child with chronic myeloid leukemia
|
03 December 2019 |
|
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia (Hijiya N et al. Blood, September 2019)
|
02 October 2019 |
|
Pediatric chronic myeloid leukemia presenting in a mixed phenotypic blast crisis: A rare occurrence (Bhattacharya J et al. Turk H Haematol, August 2019)
|
23 September 2019 |
|
The small problem when treating childhood chronic myeloid leukemia (Suttorp M et al. Pediatr Hematol Oncol, July 2019)
|
02 August 2019 |
|
Effect of imatinib on growth in children with chronic myeloid leukemia (Boddu D et al. Pediatr Hematol Oncol, July 2019)
|
02 August 2019 |
|
Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemia (Liu Y et al. AMB Express, July 2019)
|
02 August 2019 |
|
Large amplicon droplet PCR for DNA-based monitoring of pediatric chronic myeloid leukaemia (Krumbholz M et al. J Cell Mol Med, June 2019)
|
01 July 2019 |
|
Favourable of de novo advanced phases of childhood chronic myeloid leukemia (Millot F et al. Eur J Cancer, May 2019)
|
04 June 2019 |
|
How I treat chronic myeloid leukemia in children and adolescents (Hijiya N et al. Blood, March 2019)
|
03 April 2019 |
|
Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study (de Bruin CMA et al. Br J Hematol, March 2019)
|
29 March 2019 |
|
Dasatinib: A review in pediatric chronic myeloid leukemia (McCafferty EH et al. Paediatric Drugs, November 2018)
|
07 December 2018 |
|
Real-life management of children and adolescents with chronic myeloid leukemia: The Italien experience (Giona F et al. Acta Haematol, September 2018)
|
28 September 2018 |
|
Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients (Suttorp M et al. Pediatr Blood Cancer, August 2018)
|
10 September 2018 |
|
Temporal trends in the proportion of "cure" in children and young adults diagnosed with chronic myeloid leukaemia in England: a population-based study (Drozdov D et al. Pediatr Blood Cancer, August 2018)
|
10 September 2018 |
|
Dasatinib-induced Hypopigmentation in pediatric patient with chronic myeloid leukemia: A Case Report and review of the literature
|
31 August 2018 |
|
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial
|
29 June 2018 |
|
Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia (Ernst T et al. Leukemia, June 2018)
|
29 June 2018 |
|
Pediatric chronic myeloid leukemia presenting with extreme thrombocytosis simulating essential thrombocythemia (Boklan JL et al. J Pediatr Hematol Oncol, April 2018)
|
30 April 2018 |
|
Early response does not predict outcome in children and adolescents with chronic myeloid leukemia treated with high-dose imatinib (Giona F et al. Br J Hematol, March 2018) (2)
|
22 March 2018 |
|
Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: Results from a phase II trial (Gore L et al. J Clin Oncol, March 2018)
|
22 March 2018 |
|
Pharmacology and pharmacokinets of imatinib in pediatric patients (Suttorp M et al. Expert Rev Clin Pharmacol, Nov 2017)
|
22 December 2017 |
|
Prognostic discrimination based on the EUTOS long term survival score within the international registry for chronic myeloid leukemia in children and adolescents (Millot F et al. Haematologica, August 2017)
|
26 September 2017 |
|
The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy (Samis J et al. Pediatr Blood Cancer, July 2017)
|
01 August 2017 |
|
Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (Millot F et al. Cancer, May 2017)
|
06 June 2017 |
|
Death within 1 month of diagnosis in childhood cancer: an analysis of risk factors and scope of the problem (Green A et al. J Clin Oncol, March 2017)
|
28 March 2017 |
|
Flow cytometric analysis as an additional predictive tool of treatment response in children with chronic-phase chronic myeloid leukemia treated with imatinib (Shima H et al. Pediatr Blood Cancer, February 2017)
|
01 March 2017 |
|
Increased megakaryocytic proliferation, pro-platelet deposition and expression of fibrosis-associated factors in children with chronic myeloid leukemia with bone marrow fibrosis (Hussein K et al. Leukemia, February 2017)
|
01 March 2017 |
|
Early response does not predict outcome in children and adolescents with chronic myeloid leukemia treated with high-dose imatinib (Giona F et al. Br J Haematol, Dec 2016)
|
19 January 2017 |
|
Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy (Proschmann R et al. Haematologica, November 2016)
|
22 November 2016 |
|
Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America (Karalexi MA et al. Eur J Cancer, Sept 2016)
|
07 October 2016 |
|
Impact of age on the survival of pediatric leukemia: an analysis of 15083 children in the SEER database (Wang Y et al. Oncotarget, Aug 2016)
|
17 September 2016 |
|
Pediatric chronic myeloid leukemia with inv(3) (q21q26.2) and T lymphoblastic transformation: a case report (Lewen M et al. Biomark Res, July 2016)
|
17 August 2016 |
|
Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-direct chemotherapy combined with continous imatinib (Maschan A et al. Pediatr Blood Cancer, Ju
|
17 August 2016 |
|
Outcomes following bone marrow transplantation in children with accelerated phase or blast crisis chronic myelogenous leukemia in the era of tyrosine kinase inhibitors (Shulman DS et al. J Pediatr Hematol, July 2016)
|
21 July 2016 |
|
Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia (Samis J et al. Pediatr Blood Cancer, April 2016)
|
11 May 2016 |
|
Optimal management for pediatric chronic myeloid leukemia (Tanzizawe A. Pediatrics International, March 2016)
|
19 January 2017 |
|
Can chronic myleoid leukaemia in children and adolescents be successfully treated with haematopoietic stem cell transplant? A single center experience (Giona F et al. Br J Haematol, February 2016)
|
09 March 2016 |
|
Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia (Manon NN et al, Ann Hematol, January 2016
|
01 February 2016 |
|
Pediatric chronic myeloid leukemia is a unique disease that requires a different approach (Hijiya N et al. Blood, October 2015)
|
18 November 2015 |
|
Leukostasis in children and adolescents with chronic myeloid leukemia: Japanese pediatric leukemia/lymphoma study group (Kurosawa H et al. Pediatr Blood Cancer, October 2015)
|
26 October 2015 |
|
Atypical chronic myeloid leukemia in two pediatric patients (Freedman JL et al. Pediatr Blood Cancer, August 2015)
|
26 August 2015 |
|
Long-term results of high-dose imatinib in children and adolescents with CML in chronic phase: The Italian experience (Giona F et al. Br J Haematol, Apr 2015)
|
26 May 2015 |
|
Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients? (Gurrea Salas D et al. Ann Hematol, Apr 2015)
|
05 May 2015 |
|
Chronic myloid leukemia in children: clinical findings, management, and unanswered questions (Hijija N et al. Pediatr Clin North Am, February, 2015)
|
09 February 2015 |
|
Growth deceleration in children treated with imatinib for chronic myeloid leukaemia (Millot F et al. Eur J Cancer, Oct. 2014)
|
18 December 2014 |
|
Differences among young adults, adults and elderly chronic myeloid leukemia patients (Castagnetti F et al. Ann. Oncol, Oct. 2014)
|
19 November 2014 |
|
Managing children with CML: Pediatric CML Guideline if IBFM (Fuente et al. Br J Haematology, July 2014)
|
13 July 2014 |
|
Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia (Moser et al. Pediatr Blood Cancer, May 2014)
|
22 June 2014 |
|
Blood and Marrow Transplant Clinical Trials Network: progress since the State of the Science Symposium 2007 (Ferrara JL. Biol Blood Marrow Transplant, Feb. 2014)
|
22 June 2014 |
|
Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase (Millot et al. Pediatr Blood Cancer, Feb. 2014)
|
22 June 2014 |
|
Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty (Giona et al. Haematologica, Sept. 2012)
|
25 September 2012 |
|
How I treat: childhood CML (Andolina et al. Blood, Dec. 2011)
|
30 December 2011 |
|
Imatinib Has Adverse Effect on Growth in Children With Chronic Myeloid Leukemia (Bansal et al. Pediatr Blood Cancer, Nov. 2011)
|
19 November 2011 |
|
Imatinib Is Effective in Children With Previously Untreated CML in Early Chronic Phase: Results of the French National Phase IV Trial (Millot et al. J Clin Oncology, June 2011)
|
25 October 2011 |
|
CML in Children: Diagnostics and Management (Suttorp, Tauer, Millot, Publ. at 3rd Midsommer Meeting on Pediatric Hematology, June 2011)
|
20 October 2011 |
|
Pediatric phase I trial and pharmacokinetic study of dasatinib (Aplenc et al. J Clin Oncology, Nov. 2011)
|
20 October 2011 |
|
Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children with CML (Shim et al. J of Pediatrics, May 2011)
|
18 May 2011 |
|
Controversies in treatment of CML in children and adolescents: TKI versus BMT? (Suttorp et al, 2011)
|
15 February 2011 |
English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
